

BME - GROWTH

Palacio de la Bolsa
Plaza de la Lealtad, 1
28014 Madrid

Alicante, 18th of July 2022

COMMUNICATION- PRIVILEGED INFORMATION- FACEPHI BIOMETRIA, S.A.

Dear Sirs,

Under the provisions of article 17 of the Regulation (EU) No. 596/2014 on market abuse, and article 228 of the consolidated text of the Spanish Securities Market Law, approved by the Royal Legislative Decree 4/2015, of 23rd October, and related provisions, as well as in the Circular 3/2020 of BME Growth, we inform you about the following information related to the company FACEPHI BIOMETRIA, S.A. (hereinafter "FacePhi" or "the Company", indistinctly).


PRIVILEGED INFORMATION

In accordance with the provisions of section 2.2.3 of Circular 2/2020 of BME Growth, about requirements and procedures applicable to entities' increase of capital whose shares are listed on the Market, through this, Facephi makes provision thereof the following information:

The Company published as privileged information on the 25th of January 2021 the resolutions adopted by the Extraordinary General Shareholders' Meeting held on that date, which included, as the first point, the delegation to the Board of Directors of the power to issue warrants convertible into shares of the Company in favour of Nice & Green, S.A. ("Nice & Green"), with the exclusion of pre-emptive subscription rights, for a maximum conversion amount of €20,000,000, as well as to increase de share capital by the amount necessary to cover the conversion of said warrants.

On 10th June 2022, the company published the resolution adopted by the Board of Directors, under the delegation of the Company's Extraordinary General Shareholders' Meeting of January 25th, 2021, to carry out the third issue of 48,076,923 warrants convertible into shares of the Company for a maximum conversion amount of €2,500,000 (the "Equity Warrants (JUNE 2022)"), with Nice & Green being the sole subscriber of the issue of the Equity Warrants (JUNE 2022).

Nice & Green, the 8th of July 2022, under the provisions of the investment agreement, notified to the Company and exercised its right to convert 809,498 Equity Warrants (JUNE 2022) for a total conversion amount of 1,500,000 euros.



As a result of the foregoing, the Company has granted a capital increase title deed to cover the conversion of that said Equity warrants issued. The 809.498 new shares of the Company are issued with an issue price per share of 1,8530 euros, (1,813 euros as issue premium and 0.04 euros as nominal).

Following the above-mentioned capital increase, the share capital is set at the sum of 677.070,04 €, represented by 16.926.751 shares of FOUR CENTS OF EURO (€0.04) nominal value each, of the same class, equal, cumulative and indivisible.

In compliance with Circular 3/2020 of the segment BME Growth of BME MTF Equity, it is expressly stated that the information hereby communicated has been produced under the sole responsibility of the company and its administrators.

We remain at your disposal for any clarification you might deem necessary.

Sincerely,

Javier Mira Miró

Chairman of the Board of Directors